Currently, there are 123.17M common shares owned by the public and among those 121.86M shares have been available to trade.
The company’s stock has a 5-day price change of -15.41% and -12.38% over the past three months. HALO shares are trading 5.06% year to date (YTD), with the 12-month market performance up to 14.58% higher. It has a 12-month low price of $42.01 and touched a high of $70.50 over the same period. HALO has an average intraday trading volume of 1.74 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -17.46%, -18.21%, and -11.05% respectively.
Institutional ownership of Halozyme Therapeutics Inc (NASDAQ: HALO) shares accounts for 101.44% of the company’s 123.17M shares outstanding.
It has a market capitalization of $6.19B and a beta (3y monthly) value of 1.26. The stock’s trailing 12-month PE ratio is 13.33, while the earnings-per-share (ttm) stands at $3.77. The company has a PEG of 0.46 and a Quick Ratio of 7.30 with the debt-to-equity ratio at 3.13. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.25% over the week and 4.95% over the month.
Earnings per share for the fiscal year are expected to increase by 26.57%, and 33.81% over the next financial year.
Looking at the support for the HALO, a number of firms have released research notes about the stock. Leerink Partners stated their Underperform rating for the stock in a research note on May 13, 2025, with the firm’s price target at $47. Wells Fargo coverage for the Halozyme Therapeutics Inc (HALO) stock in a research note released on October 07, 2024 offered a Equal Weight rating with a price target of $62. JP Morgan was of a view on September 19, 2024 that the stock is Neutral, while Piper Sandler gave the stock Neutral rating on June 07, 2024, issuing a price target of $48- $51. TD Cowen on their part issued Outperform rating on February 29, 2024.
